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S262 Poster Session ITable 1. Correlation coefficients for parameters measured on
fresh cord blood (all p<0.0001).
TNC CFU MNC ALDHbr CD34TNC 1.00 0.70 0.82 0.58 0.50
CFU 0.70 1.00 0.61 0.66 0.60
MNC 0.82 0.61 1.00 0.47 0.41ALDHbr 0.58 0.66 0.47 1.00 0.70
CD34+ 0.50 0.60 0.41 0.70 1.00Conclusions: In this large cohort, measured fresh CB parameters
correlated well and predicted each other. Furthermore, ALDHbr
correlated well with CFUs and is a promising surrogate for CFUs
as a potency assay given the technical difficulties with the CFU assay.
In fresh CB, ALDHbr content was modestly more reliable in pre-
dicting CFUs than CD34+. We and others have shown before that
cells survive freezing and thawing with different efficiencies. We
continue to study which parameters, individually or combined, cor-
relate best with engraftment when measured on attached CBU seg-
ment or after unit thaw in order to improve potency assessment
during the final stages of donor selection.
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CYCLOPHOSPHAMIDE PRIMING WITH INTRAVENOUS PLERIXAFOR AND
GCSF MOBILIZATION FOR MULTIPLE MYELOMA
Krishnan, A.1, Wang, S.1, Htut, M.1, Farol, L.2, Palmer, J.3, Quazi, I.3,
Forman, S.1, Tsai, N.1, Forman, S.1 1City of Hope Cancer Center,
Duarte, CA; 2Southern CA Kaiser/City of Hope, Duarte, CA; 3City of
Hope, Duarte, CA
Background: Plerixafor (Pl), an inhibitor of CXCR4 has been ap-
proved for use with G-CSF for stem cell mobilization for autologous
transplant in patients withmultiplemyeloma and non-Hodgkin lym-
phoma. However, the subcutaneous route of injection necessitates
dosing 11 hours prior to apheresis. Intravenous (IV) dosing may re-
sult in a faster peak CD34+ cell count allowingmore convenient dos-
ing. Other strategies to increase stem cell yield include
chemotherapy mobilization with cyclophosphamide (CY). Herein
we report on the use of CY followed by intravenous Pl plus G-CSF.
Methods: The primary objectives were safety and efficacy of intra-
venous administration of Pl following CY mobilization in pts with
myeloma. The secondary endpoint was the ability to collect .5 x
106 CD34+ cells/kg in two or fewer days. Patients received CY
1.5g/m2 followed byG-CSF (10mg/kg) 24 hrs post chemo. Apheresis
commenced 10 days post CY, Pl IV (0.16-0.24mg/kg) was given on
the morning of apheresis, 4-6 hrs prior to apheresis. Peripheral
CD34+ cell counts were drawn just before Pl administration and at
1- 4 hr time points post.
Results: Eleven patients have been enrolled to date and are available
for analysis;median age is 59.2 (range: 43.4 – 68.9) years, median no. of
prior therapies is 1 (range: 1-3). Three pts were treated with 0.16mg/
kg, 8 with 0.24mg/kg of Pl. Eight patients had prior lenalidomide and
9 had prior bortezomib. Disease status at entry was 2 CR, 1MR, 6 PR
and 2 VGPR. CD34 counts increased a median of 1.8 fold (range: 1.1-
2.9) 1 hr post the first IV dose.
Seven of eleven pts met the secondary endpoint. Nine pts have been
transplanted and all engrafted at a median of 11 days (range 10-12) for
neutrophil engraftment and 16 days for plts (range 8-22). Grade 3/4
non heme toxicities occurred in ten pts and included emesis, anorexia,
hyperglycemia, hyperuricemia, hyponatremia and bone pain.
Conclusions: The adverse event profile and efficacy of IV Pl post
chemotherapy is similar to subcutaneous administration, with the ex-
ception of chemo related toxicities and allows for same day dosing of
Pl as apheresis.158
HIGH-RESOLUTION MULTIDIMENSIONAL PROTEOMIC ANALYSIS OF
CIRCULATING BIOMARKERS IN PATIENTS WITH ACUTE GRAFT-VER-
SUS-HOST DISEASE (aGVHD)
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Introduction:The graft-versus-host disease is a serious complication
of allogeneic hematopoietic stem cells transplantation (HSCTs) and
the major cause of morbidity and mortality in patients undergoing
this therapy. The diagnosis of aGVHD is still carried out by clinical
observations followed by biopsies of injured organs. Thus, studies
that aim to identify potential biomarkers for aGVHD are needed.
Multidimensional proteomic strategies on a large scale have been
widely used for the identification and quantification of biomarkers in
different diseases. Therefore the identification and absolute quantifi-
cation of proteins and peptides differentially expressed in the plasma
of patients who developed aGVHD, is extremely important.
Objective: Compare and quantify the protein expression profile of
the patients plasma after allogeneic HSCT comparing patients
who developed aGVHD with those that did not develop aGVHD
and the plasma of healthy donors.
Materials and Methods: This study analyzed 73 plasma samples of
patients who underwent allogeneic HSCT at D+45 and 50 plasma
samples from healthy donors. 31 samples had acute myeloid leuke-
mia (AML) as underlying disease, 21 patients developed aGVHD
and 10 patients did not develop aGVHD. 42 patients had as under-
lying disease acute lymphoblastic leukemia (ALL), 24 and 18 devel-
oped aGVHDor did not develop aGVHD respectively. The samples
were concentrated 16x with 3k Amicon columns (Millipore) and
digested in solution and analyzed bymultidimensional chromatogra-
phy (MudPIT) in mass spectrometry-2D-NanoESI MSE (MudPIT)
using Synapt HDMS mass spectrometer (Waters). The proteins
were identified and quantified using the software Proteinlynks
Global Server (Waters) with the tool Expression E.
Results and Conclusions: We identified 99 and 109 proteins in
AML and ALL respectively. Differential expression analysis identified
102 proteins between the pools of samples compared. Among the pro-
teins identified protein NALP2 stands out as a possible biomarker of
aGVHD in patients who had AML as the underlying disease.
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IMPACT OF GRAFT CD34 CELL DOSE ON CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AND PREDICTIVE VALUES OF CD3 CELL DOSE AND
DAY 56 CHIMERISM ON SURVIVAL IN NONMYELOABLATIVE (NMA) AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Pecheux, L., Ahmad, I., Baron, C., Busque, L., Cohen, S., Kiss, T.,
Roy, D.-C., Roy, J., Sauvageau, G., Lachance, S. Ho^pitalMaisonneuve-R-
osemont, Montreal, QC, Canada
Purpose:Compared tomyeloablative regimensNMAHSCT is asso-
ciated with decreased toxicity but higher incidence of cGVHD and re-
lapse. The optimalCD34+ cell dose inNMAHSCTand the impact of
graft composition on transplant outcome remains controversial.
We studied the influence of graft composition, engraftment kinet-
ics and post-transplant chimerism on outcomes in this setting.
Methods: We retrospectively analyzed graft composition and chi-
merism data in a homogenous cohort of 81 consecutive patients
treated for multiple myeloma with HLA-matched sibling NMA
HSCTafter a conditioning regimen based on FluCy. All patients un-
derwent an autologous followed by a NMA allogeneic HSCT in
a tandem approach. GVHD prophylaxis combined tacrolimus and
mycophenolate mofetil (MMF). MMF was stopped at day +50 and
tacrolimus tapered between day+80 and day+100. FDC was defined
as . 5 95% donor CD3 circulating cells.
Results: Progression-free (PFS) and overall survival (OS) at 8 years
was respectively 42,7% and 70.7%. All but 8 patients achieved FDC
at day 180. Median time from transplantation to FDC was 120 days.
Four out of the 8 patients with persistent mixed chimerism (MC) ex-
perienced progression, 2 of them before day 100. Graft composition
in CD3 and CD34 cells were correlated (r 5 0.291, P 5 0.009).
CD34 \ 5 x10^6/kg was associated with less cGVHD (73% vs
92% p 5 0,039). CD3\ 25 x10^7/kg was associated with better
